Major determinants of hyperhomocysteinemia in peritoneal dialysis patients

Kidney International

Volumn 53, Issue 6, 1998, Pages 1775-1782

  Vychytil, Andreas ^b   Födinger, Manuela ^b   Wölfl, Gabriele ^b   Enzenberger, Brigitte ^b   Auinger, Martin ^b   Prischl, Friedrich ^b   Buxbaum, Martina ^b   Wiesholzer, Martin ^b   Mannhalter, Christine ^b   Hörl, Walter H ^b   Sunder Plassmann, Gere ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Folate; Methylenetetrahydrofolate reductase; Mutation; Peritoneal dialysis; Polymorphism; Total homocysteine; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALBUMIN; CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; GENE FREQUENCY; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; VITAMIN INTAKE;

EID: 7144226583     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00918.x     Document Type: Conference Paper

References (39)

1. BACHMANN J, TEPEL M, RAIDT H, RIEZLER R, GRAEFE U, LANGER K, ZIDEK W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6:121-125, 1995
2. BOSTOM AG, SHEMIN D, LAPANE KL, MILLER JW, SUTHERLAND P, NADEAU M, SEYOUM E, HARTMAN W, PRIOR R, WILSON PWF, SELHUB J: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 114:93-103, 1995
3. ROBINSON K, GUPTA A, DENNIS V, ARHEART K, CHAUDHARY D, GREEN R, VIGO P, MAYER EL, SELHUB J, KUTNER M, JACOBSEN DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743-2748, 1996
4. BOSTOM AG, SHEMIN D, LAPANE KL, NADEAU MR, SUTHERLAND P, CHAN J, ROZEN R, YOBURN D, JACOUES PF, SELHUB J, ROSENBERG IH: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123:193-202, 1996
5. CHAUVEAU P, CHADEFAUX B, COUDÉ M, AUPETIT J, HANNEDOUCHE T, KAMOUN P, JUNGERS P: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43(Suppl 41): S72-S77, 1993
6. FROSSI P, BLOM HJ, MILOS R, GOYETTE P, SHEPPARD CA, MATTHEWS RG, BOERS GJH, DEN HEIJER M, KLUIJTMANS LAJ, VAN DEN HEUVEL LP, ROZEN R: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet 10:111-113, 1995
7. DE FRANCHIS R, MANCINI FP, D'ANGELO A, SEBASTIO G, FERMO I, DE STEFANO V, MARGAGLIONE M, MAZZOLA G, DI MINNO G, ANDRIA G: Elevated total plasma homocysteine and 677C → T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 59: 262-264, 1996
8. GALLAGHER PM, MELEADY R, SHIELDS DC, TAN KS, MCMASTER D, ROZEN R, EVANS A, GRAHAM IM, WHITEHEAD AS: Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 94:2154-2158, 1996
9. JACOUES PF, BOSTOM AG, WILLIAMS RR, ELLISON RC, ECKFELDT JH, ROSENBERG IH, SELHUB J, ROZEN R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93:7-9, 1996
10. FÖDINGER M, MANNHALTER C, WÖLFL G, PABINGER I, MÜLLER E, SCHMID R, HÖRI WH, SUNDER-PLASSMANN G: Mutation (677 C to T) in the methylenetetrahydofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52:517-523, 1997
11. HULTBERG B, ANDERSSON A, STERNER G: Plasma homocysteine in renal failure. Clin Nephrol 40:230-234, 1993
12. JANSSEN MJFM, VAN DEN BERG M, VAN GULDENER C, BOERS GHJ, STEHOUWER CDA: Withdrawal of folic acid supplementation in maintenance hemodialysis patients. (letter) Clin Nephrol 42:136-137, 1994
13. JANSSEN MJFM, VAN GULDENER C, DE JONG GMT, VAN DEN BERG M, STEHOUWER CDA, DONKER AJM: Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 22:110-114, 1996
14. KIM SS, HIROSE S, TAMURA H, NAGASAWA R, TOKUSHIMA H, MITARAI T, ISODA K: Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients. Adv Perit Dial 10:282-285, 1994
15. HOLDT B, KORTEN G, KNIPPEL M, LEHMANN JK, CLAUS R, HOLTZ M, HAUSMANN S: Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Perit Dial Int 16(Suppl 1):S246-S249, 1996
16. ARNADOTTIR M, BRATTSTRÖM L, SIMONSEN O, THYSELL H, HULTBERG B, ANDERSSON A, NILSSON-EHLE P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40:236-240, 1993
17. ARAKI A, SAKO Y: Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422:43-52, 1987
18. ROBINS AJ, MILEWCZYK BK, BOOTH EM, MALLICK NP: Plasma amino acid abnormalities in chronic renal failure. Clin Chim Acta 42:215-217, 1972
19. WILCKEN DEL, GUPTA VJ, REDDY SG: Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin Sci 58:427-430, 1980
20. KANG SS, WONG PWK, BIDANI A, MILANEZ S: Plasma protein-bound homocyst(e)ine in patients requiring chronic haemodialysis. Clin Sci 65:335-336, 1983
21. SMOLIN LA, LAIDLAW SA, KOPPLE JD: Altered plasma free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis. Am J Clin Nutr 45:737-743, 1987
22. LAIDLAW SA, SMOLIN LA, DAVIDSON WD, KOPPLE JD: Sulfur amino acids in maintenance hemodialysis patients. Kidney Int 32(Suppl 22):S191-S196, 1987
23. FRIEDMAN JA, DWYER JT: Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Nutr Rev 53:197-201, 1995
24. WILCKEN DEL, DUDMAN NPB, TYRRELL PA, ROBERTSON MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37:647-701, 1988
25. BOSTOM AG, SHEMIN D, LAPANE KL, HUME AL, YOBURN D, NADEAU MR, BENDICH A, SELHUB J, ROSENBERG IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147-152, 1996
26. WILCKEN DEL, GUPTA VJ: Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 9:301-307, 1979
27. CEBALLOS I, CHAUVEAU P, GUERIN V, BARDET J, PARVY P, KAMOUN P, JUNGERS P: Early alterations of plasma free amino acids in chronic renal failure. Clin Chim Acta 188:101-108, 1990
28. SORIA C, CHADEFAUX B, COUDE M, GAILLARD O, KAMOUN P: Concentrations of total homocysteine in plasma in chronic renal failure. Clin Chem 36:2137-2138, 1990
29. HULTBERG B, AGARDH E, ANDERSSON A, BRATTSTRÖM L, ISAKSSON A, ISRAELSSON B, AGARDH CD: Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 51:277-282, 1991
30. BOSTOM A, BROSNAN JT, HALL B, NADEAU MR, SELHUB J: Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116:59-62, 1995
31. PERNA AF, INGROSSO D, DE SANTO NG, GALLETTI P, ZAPPIA V: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 47:247-253, 1995
32. PERNA AF, INGROSSO D, GALLETTI P, ZAPPIA V, DE SANTO NG: Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int 50:358-366, 1996
33. PERNA AF, INGROSSO D, ZAPPIA V, GALLETTI P, CAPASSO G, DE SANTO NG: Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest 91: 2497-2503, 1993
34. MUDD SH, UHLENDORF BW, FREEMAN JM, FINKELSTEIN JD, SHIH VE: Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. Biochem Biophys Res Commun 46:905-912, 1972
35. KANG SS, WONG PWK, BOCK HGO, HORWITZ A, GRIX A: Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 48:546-551, 1991
36. ALETHAN G, ARO A, GEY KF: Plasma homocysteine and cardiovascular disease mortality. (letter) Lancet 349:397, 1997
37. MOLLOY AM, DALY S, MILLS JL, KIRKE PN, WHITEHEAD AS, RAMSBOTTOM D, CONLEY MR, WEIR DG, SCOTT JM: Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations. Lancet 349:1591-1593, 1997
38. LAMEIRE N, VANHOLDER RC, VAN LOO A, LAMBERT MC, VIJT D, VAN BOCKSTAELE L, VOGELLEFRE P, RINGOIR SM: Cardiovascular diseases in peritoneal dialysis patients: The size of the problem. Kidney Int 50(Suppl 56):S28-S36, 1996
39. WHEELER DC: Cardiovascular disease in patients with chronic renal failure. Lancet 348:1673-1674, 1996